Evvy Secures $40 Million Series B to Supercharge Women’s Health Research with Vaginal Microbiome Data

When Evvy announced its latest funding round on a bright Tuesday morning, the buzz was palpable. The San Francisco‑based startup just closed a $40 million Series B, with Catalio Capital Management taking the lead. It’s a hefty cheque, but for a company that began in 2021 with three founders—Priyanka Jain, Laine Bruzek, and Pita Navarro—it feels like the fuel for a long‑planned sprint.

What sets Evvy apart isn’t just the money; it’s the technology. The firm runs what it calls the world’s only at‑home, CLIA‑ and CLEP‑certified metagenomic next‑generation sequencing (mNGS) test that profiles the vaginal microbiome from a single swab. You collect the sample at home, mail it back to Evvy’s lab, and a cloud‑based pipeline turns raw DNA into a detailed report. The results land in a personal health portal, complete with a clinical interpretation, a diagnosis, and clear next‑step recommendations—sometimes even a personalized prescription.

Since launching, Evvy says it’s already served more than 100,000 patients across the United States and has partnered with roughly 3,000 clinicians. The company has also generated a respectable body of scientific work—15 peer‑reviewed publications, a handful of novel bacterial vaginosis subtypes, and hundreds of previously uncatalogued vaginal‑microbe genomes.

All of that data, however, is just the tip of the iceberg for Jain. “Precision medicine for women has been hamstrung by the lack of high‑quality, representative data on female bodies,” she told TechCrunch. “You can’t train AI models on datasets that ignore women’s biology.” Her answer is to marry AI with the massive, constantly growing microbiome dataset Evvy is amassing.

In May, the startup rolled out EvvyAI, an in‑app assistant that translates raw microbial signatures into plain‑language advice and routes users to clinicians when a human touch is required. The AI isn’t meant to replace doctors; rather, it serves as a first‑line guide, flagging potential issues and suggesting lifestyle tweaks while the clinician reviews the deeper molecular findings.

But Evvy isn’t stopping at vaginal health. The company is stepping into fertility, a natural extension of its mission. A prospective study launched last year is already pairing the microbiome test with IVF clinics, looking for links between microbial composition and outcomes such as implantation success, preterm birth risk, and even gynecologic cancers. Jain hopes that, with enough data, the “unexplained” labels that haunt patients—unexplained infertility, recurrent pregnancy loss, mysterious symptoms—will become relics of the past.

In the longer view, Jain envisions a next‑generation Pap smear: an at‑home, non‑invasive sample that offers a continuous stream of data on infections, inflammation, hormonal shifts, fertility, endometriosis, pre‑menopause, HPV progression, and more. “We can’t wait for traditional research pipelines to catch up,” she says. “Women themselves can push the science forward by sharing their data.”

Evvy isn’t alone in this space. Competitors such as Juno Bio, Tiny Health, and Daye are also exploring at‑home microbiome diagnostics, but Evvy’s blend of certified lab work, AI assistance, and a clear ambition to build a longitudinal dataset gives it a distinctive edge.

With the fresh $40 million infusion, Evvy plans to double down on research, expand its clinician network, and sharpen the AI that powers EvvyAI. If all goes well, the next few years could see women accessing richer, data‑driven insights about their own bodies without ever stepping foot in a lab.